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Abstract 1
We have shown that mucosal HIV-1 recombinant pox viral vaccination can induce 2
high avidity HIV-specific CD8+ T cells with reduced interleukin (IL)-4 and IL-13 3
expression compared to systemic vaccine delivery. In the current study how these 4
cytokines act to regulate anti-viral CD8+ T cell avidity following HIV-1 recombinant 5
pox viral prime-boost vaccination was investigated. Out of a panel of T cell avidity 6
markers tested, only CD8 expression levels were found to be enhanced on KdGag197-7
205 (HIV)-specific CD8+ T cells obtained from IL-13 -/-, IL-4 -/- and signal transducer 8
and activator of transcription of 6 (STAT6) -/- mice compared to wild-type (WT)9
controls following vaccination. Elevated CD8 expression levels in this instance also10
correlated with polyfunctionality (interferon (IFN)-J, tumour necorsis factor (TNF)-D11
and IL-2 production) and the avidity of HIV-specific CD8+ T cells. Furthermore,12
mucosal vaccination and vaccination with the novel adjuvanted IL-13 inhibitor (i.e. 13
IL-13RD2) vaccines significantly enhanced CD8 expression levels on HIV-specific 14
CD8+ T cells, which correlated with avidity. Using anti-CD8 antibodies that blocked 15
CD8 availability on CD8+ T cells, it was established that CD8 played an important 16
role in increasing HIV-specific CD8+ T cell avidity and polyfunctionality in IL-4 -/-,17
IL-13 -/- and STAT6 -/- mice compared to WT controls following vaccination.  18
Collectively, our data demonstrate that IL-4 and IL-13 dampen CD8 expression levels 19
on anti-viral CD8+ T cells, which can down-regulate anti-viral CD8+ T cell avidity 20
and polyfunctionality following HIV-1 recombinant pox viral vaccination. These 21
findings can be exploited to design more efficacious vaccines not only against HIV-1,22
but many chronic infections where high avidity CD8+ T cells help protection.23
Keywords: CD8+ T cell avidity/polyfunctionality; HIV-1 vaccines/vaccination; CD8 24
expression; IL-4/IL-13; mucosal vaccination25
1. Introduction 21 
Even though effective anti-retroviral drugs are currently available against HIV-1 [1], 22 
developing a vaccine still remains a major priority for slowing down the progression of 23 
HIV-1 incidences worldwide. Unfortunately, this has been a daunting task given the 24 
capacity of HIV-1 to maintain latency and mutate rapidly allowing it to evade the 25 
immune system [2]. Furthermore, many of the past HIV-1 vaccines that have elicited 26 
protective outcomes in animals have failed to do so in humans [3-8].  27 
 28 
The induction of high avidity anti-viral CD8+ T cells responses is thought to be critical 29 
for effective protective immunity against viruses including HIV-1 [9, 10]. Various 30 
molecules that facilitate cell adhesion (e.g. CD2 and CD11a), cognate peptide-major 31 
histocompatibility class I complexes (pMHC-I) recognition (i.e. densities of CD8 and T 32 
cell receptor (TCR) interaction) and intracellular signaling such as lck have been known 33 
to regulate T cell avidity [11-14]. High avidity anti-viral CD8+ T cells can recognize 34 
and respond to lower densities of cognate pMHC-I on virus-infected cells compared to 35 
low avidity anti-viral CD8+ T cells [15]. This allows high avidity HIV-specific CD8+ T 36 
cells to minimise or prevent the spread of this virus from early exposed genito-rectal 37 
mucosae to the gut where the greatest CD4+ T cell depletion occur during HIV-1 38 
infection [2, 10]. High avidity anti-viral CD8+ T cells are also polyfunctional (i.e. 39 
produce multiple anti-viral/survival cytokines such as IFN-γ, TNF-D and IL-2) [16-17]. 40 
Numerous studies have demonstrated that elite controllers of HIV-1 infection maintain 41 
more high avidity and polyfunctional CD8+ T cells than non-controllers [18-20]. 42 
Therefore, development of vaccines that can induce high avidity HIV-specific CD8+ T 43 
cells could be extremely beneficial for optimising protective outcomes against HIV-1.  44 
 45 
Despite the knowledge that high avidity anti-viral CD8+ T cells are important for 46
efficient virus control, the mechanisms responsible for enhancing the avidity of anti-47
viral CD8+ T cells following vaccination is not well understood. Previous studies have 48
shown that IL-4 and IL-13 can modulate anti-viral efficacy of CD8+ T cells and control49
of virus infection [21-24]. We have shown that HIV-specific CD8+ T cells that develop 50
following mucosal (intranasal (i.n.)/i.n. or i.n./intramuscular (i.m.)) compared to purely 51
systemic (i.m./i.m.) HIV-1 recombinant pox viral prime-boost vaccination have reduced 52
expression of IL-4/IL-13, but are higher in avidity [25].  In subsequent studies, we have 53
shown following pox viral infection and HIV-1 recombinant pox viral prime-boost 54
vaccination that IL-4, IL-13 and STAT6 can dampen the avidity and polyfunctionality 55
of anti-viral CD8+ T cells [26-27].  Based on this knowledge we have now developed a56
novel HIV-1 recombinant pox viral IL-13 receptor D2 (IL-13RD2) adjuvanted vaccine57
that can be used to transiently inhibit IL-13 activity at the vaccination site [24]. This 58
vaccine was shown to enhance the avidity/polyfunctionality of HIV-specific CD8+ T59
cells as well as the protective efficacy [24]. Given that pox virus vectors are commonly 60
used in vaccination studies, here we have addressed how IL-4 and IL-13 can dampen 61
the avidity of anti-viral CD8+ T cells following HIV-1 recombinant pox viral 62
vaccination with the hope of developing more effective HIV-1 vaccines that translate 63
into future phase I clinical trials.64
65
2. Materials and methods66
2.1 Mice67
Pathogen-free 6-8 weeks old female WT, IL-4 -/-, IL-13 -/-, and STAT6 -/- BALB/c mice 68
were all purchased from the Australian Phenomics Facility, the Australian National 69
University. All the mice were handled and maintained under the Australian National 70
University Animal Experimentation and Ethics Committee approved guidelines and 71
protocol number A2011/018.  72
73
2.2 Recombinant HIV-1 prime-boost vaccination and vaccinia virus infection74
The recombinant fowlpox virus vectors encoding HIV-1 AE clade Gag, Pol and Env  75
(FPV-HIV) and recombinant vaccinia virus encoding HIV-1 AE clade Gag and Pol 76
(VV-HIV) used in the current study were exactly as those used previously in 77
Ranasinghe et al [28]. Recombinant FPV-HIV and VV-HIV co-expressing the murine 78
soluble IL-13RD2 (IL-13 inhibitor vaccines) were constructed exactly as describe in 79
[24]. 80
81
Vaccinia virus Western Reserve (VV-WR) strain and infection with this virus was 82
exactly as described in Wijesundara et al [26]. Briefly, BALB/c mice were infected for 83
7 days intraperitoneally (i.p.) prior to isolation of splenocytes for flow cytometry 84
analysis. For all recombinant HIV-1 prime-boost vaccinations except where indicated, 85
pathogen free 6-8 weeks old BALB/c mice were primed i.n. with 1 x 107 PFU of FPV-86
HIV followed by i.m. booster vaccination with 1 x 107 PFU of VV-HIV 14 days apart87
as described in Ranasinghe et al [28]. T cell responses were evaluated 14 days post 88
booster vaccination.89
90
2.3 Flow cytometry 91
Monoclonal antibodies against mouse antigens CD2 (clone RM2-5), CD11a (clone 92
2D7), TCRE (clone H57-597), IFN-J (clone XMG1.2), H-2Kd (clone SF1-1.1) and 93
CD8E.2 (clone 53-5.8) were all purchased from BioLegend with the exception of CD8D94
(clone 53-6.7), lck (clone MOL 171) and TNF-D (clone MP6-XT22), which were 95
purchased from Becton Dickinson (BD) Biosciences. These antibodies were used as 96
purified (not conjugated) or conjugated with fluorescein isothiocyanate, phycoerythrin, 97
peridinin chlorophyll protein, allophycocyanin or pacific blue. Peridinin chlorophyll 98
protein conjugated monoclonal antibody against mouse IL-2 (clone JES6-5H4) was 99
purchased from eBioscience. All cell surface and intracellular staining procedures with100
these antibodies were performed as described previously [26]. Stained samples were 101
analysed using the BD FACScalibur or BD LSR II prior to analysis using the FlowJo 102
Tree Star software (version 8.8.7). For each sample 2 x 105 – 1 x 106 events were 103
acquired.   104
 105
2.4 Tetramer staining and dissociation assays106
Allophycocyanin conjugated KdA5275-83 or KdGag197-205 tetramers were synthesized by 107
the Biomolecular Resource Facility, the John Curtin School of Medical Research.108
Tetramer staining was done using red blood cell (RBC)-depleted single cell suspensions109
from the spleens of vaccinated mice exactly as that described in Ranasinghe et al [25].110
For blocking CD8 engagement with KdGag197-205 tetramer, cells (2 x 106 cells/25 Pl111
phosphate buffer saline (PBS)) were incubated with varying concentrations of purified 112
anti-mouse CD8E.2 for 30 minutes at 4 qC prior to tetramer staining.  When tetramer 113
dissociation was performed, tetramer stained cells were incubated for 60 minutes at 37 114
qC + 5% CO2 in the presence of 25 Pg/ml of anti-mouse H-2Kd (2 x 106 cells/40 Pl 115 
PBS) to prevent tetramer re-binding to cells. After tetramer staining and/or dissociation, 116 
cells were washed twice using PBS + 1 % fetal calf serum (FCS) prior to conducting a 117 
cell surface stain.  118 
  119 
2.5 Peptide stimulation for intracellular cytokine staining (ICS) 120 
H-2Kd restricted Gag197-205 (AMQMLKETI) peptides were synthesized at the 121 
Biomolecular Resource Facility, the John Curtin School of Medical Research. KdGag197-122 
205 peptide stimulation of splenocytes was performed similar to that described 123 
previously [26]. Briefly, 4 x 106 RBC-depleted splenocytes resuspended in 200 Pl of 124 
RPMI + 10% FCS were incubated for 1 hour at 37 qC + 5% CO2 in the presence or 125 
absence of 0.1 Pg/ml of KdGag197-205 peptide. Subsequently, each culture was incubated 126 
with 1x brefeldin A (eBioscience) for further 4 hours at 37 qC + 5% CO2 prior to cell 127 
surface and intracellular staining. When CD8 blocking was performed, cells were 128 
incubated with 1 Pg/ml of purified anti-mouse CD8E.2 prior to and during KdGag197-205 129 
peptide stimulation. 130 
 131 
Statistical analysis 132 
 Mean fluorescent intensity (MFI) values and flow cytometry plots were obtained 133 
following analysis of data using FlowJo Tree Star software (version 8.8.7). The data 134 
plotted in all the graphs represent the mean and the error bars depict the standard error 135 
of the mean (SEM). Statistical significance of the data and the p values were calculated 136 
using the Graph InStat software (version 3.10). In all statistical significance analysis, a 137 
student’s t-test or one-way analysis of variance (ANOVA) was used. The p values are 138 
denoted as follows: ns - p > 0.05, * - p < 0.05, ** - p < 0.01, and *** - p < 0.001.    139 
140 
3. Results 141
3.1 IL-4 and IL-13 selectively dampen CD8 expression levels on HIV-specific CD8+ T142
cells 143
We initially examined whether IL-4 and IL-13 regulated the expression of T cell 144
associated molecules, which could dampen the avidity of anti-viral CD8+ T cells 145
induced following HIV-1 recombinant pox viral prime-boost vaccination. For this 146
purpose, the expression of a representative panel of T cell avidity markers (i.e. CD8, 147
lck, TCRE, CD2 and CD11a) were measured on KdGag197-205-specific CD8+ T cells that 148
were induced following i.n. FPV-HIV/i.m. VV-HIV vaccination of WT, IL-13 -/-, IL-4 -149
/- and STAT6 -/- BALB/c mice (Fig. 1A and 1B). 150
151
Following HIV-1 recombinant prime boost vaccination, only CD8D and CD8E levels 152
were found to be consistently enhanced on KdGag197-205-specific CD8+ T cells obtained 153
from gene knockout mice relative to the WT controls (Fig. 1A and 1B). Although some 154
reports have suggested that high avidity anti-viral CD8+ T cells can enhance the 155
expression ratios of CD8E:CD8D [29], these ratios were similar on KdGag197-205-specific 156
CD8+ T cells from all vaccinated animals (Fig. 1C). IL-4 and IL-13 mediated reduction 157
of CD8 densities was also observed on KdA52R75-83-specific CD8+ T following VV-WR 158
infection suggesting that this was phenomenon was not specific to KdGag197-205-specific 159
CD8+ T cells (Fig. 1D). Our previous studies have demonstrated that the avidity of 160
KdGag197-205-specific CD8+ T cells can be regulated depending on the route of vaccine 161
delivery (i.e. avidity: i.n./i.n. > i.n./i.m. > i.m./i.m.) [25]. The avidity hierarchy from this 162
published report correlated with the CD8 expression levels on KdGag197-205-specific 163
CD8+ T cells (i.e. CD8 expression: i.n./i.n. > i.n./i.m. > i.m./i.m.) in the current study 164
(Fig. 1E). Furthermore, we have recently shown that vaccines that transiently inhibit IL-165
13 activity at the vaccination site can induce high avidity CD8+ T cells with better 166 
protective efficacy (i.e. avidity and protection: IL-13RD2 adjuvanted IL-13 inhibitor 167 
vaccine > control vaccine) [24]. In the current study, compared to the control 168 
vaccination (i.n. FPV-HIV/i.m. VV-HIV), IL-13 inhibitor vaccination strategy (i.n. 169 
FPV-HIV-IL-13RD2/i.m. VV-HIV-IL-13RD2) also facilitated the development of 170 
KdGag197-205-specific CD8+ T cells with elevated CD8 expression levels (Fig. 1F). 171 
Collectively, our data demonstrated that IL-4 and/or IL-13 can down-regulate CD8 172 
expression levels, which correlated with reduced avidity on anti-viral CD8+ T cells.  173 
 174 
3.2 Regulation of CD8 expression levels is a feature of CD8+ T cell polyfunctionality  175 
In order to further understand the involvement of CD8 in modulating CD8+ T cell 176 
avidity following HIV-1 vaccination, we next examined how the expression levels of 177 
CD8 were regulated on different polyfunctional subsets of HIV-specific CD8+ T cells. 178 
Highly polyfunctional anti-viral CD8+ T cells have been reported to produce IFN-J, 179 
TNF-D and IL-2 compared to poorly polyfunctional anti-viral CD8+ T cells, which 180 
predominantly produce IFN-J [30]. Therefore, we next measured the CD8 expression 181 
levels on IFN-J+ TNF-D+ IL-2+ (highly polyfunctional), IFN-J+ TNF-D+ IL-2- 182 
(moderately polyfunctional) and IFN-J+ TNF-D- IL-2- (poorly polyfunctional) KdGag197-183 
205-specific CD8+ T cells following i.n. FPV-HIV/i.m. VV-HIV vaccination (Fig. 2). 184 
IFN-J was monitored (Fig. 2B and 2C) as a positive control given that highly 185 
polyfunctional T cells have been reported to produce more IFN-J on a per cell basis 186 
compared to poorly polyfunctional T cells [31].  Greatly elevated CD8D and CD8E 187 
levels were detected in highly polyfunctional compared to poorly/moderately 188 
polyfunctional KdGag197-205 specific CD8+ T cells (Fig. 2B and 2C). Overall, increasing 189 
CD8 expression levels appeared to be a feature of anti-viral CD8+ T cells that were 190
highly polyfunctional following HIV-1 recombinant pox viral prime-boost vaccination.191
192
3.3 HIV-specific CD8+ T cells require CD8 for optimal cognate pMHC-I engagement 193
The studies presented thus far suggest that regulation of CD8 on anti-viral (i.e. 194
KdGag197-205-specific) CD8+ T cells correlate with enhancement in T cell avidity and 195
polyfunctionality. However, CD8 null tetramer studies have shown that TCR 196
engagement alone on effector CD8+ T cells could be sufficient for maintaining a high 197
avidity interaction with cognate pMHC-I [32]. Therefore, we next examined whether 198
the availability of CD8 on KdGag197-205-specific CD8+ T cells was important in 199
maintaining a high avidity interaction with cognate pMHC-I.200
201
In order to achieve the above, splenocytes obtained from i.n. FPV-HIV/i.m. VV-HIV 202
vaccinated mice were incubated with increasing concentrations of purified anti-CD8E.2203
to limit the availability of CD8 molecules prior to KdGag197-205 tetramer staining (Fig. 204
3). Data demonstrated a dose dependent reduction of KdGag197-205-tetramer engagement 205
with increasing concentrations of anti-CD8E.2 (Fig. 3). Therefore, our data indicated206
that CD8 on KdGag197-205-specific CD8+ T cells was crucial for maintaining a high 207
avidity interaction with cognate pMHC-I molecules.    208
209
3.4 IL-4 and IL-13 mediated CD8 density regulation on HIV-specific CD8+T cells 210
modulate T cell avidity/polyfunctionality 211
We next examined whether IL-4 and IL-13 mediated reduction of CD8 densities (Fig. 1) 212
could also dampen the avidity of HIV-specific CD8+ T cells from WT controls 213
compared to IL-13 -/-, IL-4 -/- and STAT6 -/- BALB/c mice. For this purpose, splenocytes 214
from i.n. FPV-HIV/i.m. VV-HIV vaccinated mice were incubated with or without anti-215
CD8E.2 prior to conducting an ICS for measuring polyfunctionality or tetramer 216
dissociation assay for measuring avidity. The rationale here was that if reduction of 217
CD8 densities on HIV-specific CD8+ T cells was important then blocking CD8 218
availability for tetramer engagement and cytokine production should abrogate avidity 219
differences observed between IL-13 -/-, IL-4 -/- and STAT6 -/- BALB/c mice and WT 220
controls.221
222
In the absence of CD8 blocking (mock) greater proportion of IFN-J producing 223
KdGag197-205-specific CD8+ T cells were found to express TNF-D and IL-2 in IL-13 -/-,224
IL-4 -/- and STAT6 -/- BALB/c mice compared to BALB/c WT mice (Fig. 4A and 4C).225
The absolute numbers of IFN-J+ TNF-D+ IL-2+ KdGag197-205 specific CD8+ T cells were 226
also enhanced in the gene knockout mice (Fig. 4B). Furthermore, in the absence of CD8 227
blocking the amount of tetramer dissociation that occurred on WT KdGag197-205 specific 228
CD8+ T cells was greater than that of the gene knockout mice following vaccination 229
(Fig. 4D). Collectively these findings are consistent with previous reports, which have 230
shown that greater proportion of high avidity anti-viral CD8+ T cells express TNF-D231
and IL-2 in addition to IFN-J compared to low avidity anti-viral CD8+ T cells [33].232
233
Significant reduction in the proportion of IFN-J producing CD8+ T cells that also 234
expressed TNF-D and IL-2 was observed in all vaccinated animals when CD8 235
availability for splenocytes was blocked during KdGag197-205 peptide stimulation (Fig. 236
4C). CD8 blocking of splenocytes from all vaccinated mice also reduced the amount of 237
KdGag197-205 tetramer engagement by CD8+ T cells during tetramer dissociation (Fig. 238
4D). Furthermore, statistically significant enhancement in KdGag197-205 tetramer 239
dissociation of CD8+ T cells from WT mice was not observed relative to the gene 240 
knockout mice when CD8 was blocked on splenocytes during tetramer dissociation 241 
(Fig. 4D).  Similarly, statistically significant enhancement in the proportions of IFN-J+ 242 
KdGag197-205 CD8+ T cells that produced TNF-D and IL-2 was not observed in 243 
vaccinated gene knockout mice relative to WT mice when CD8 was blocked on 244 
splenocytes during KdGag197-205 peptide stimulation (Fig. 4D). Thus, up-regulation of 245 
CD8 expression levels on KdGag197-205 CD8+ T cells from gene knockout mice appeared 246 
to be important in enhancing avidity and polyfunctionality.   247 
248 
4. Discussion 249
Due to the disappointing outcomes of numerous HIV-1 vaccine trials conducted thus 250
far, development of more efficacious HIV-1 vaccines is a necessity for slowing the 251
global progression of HIV-1. This requires the fundamental understanding of 252
mechanisms that generate favourable immune outcomes following vaccination. In 253
previous studies, we have shown that following HIV-1 recombinant pox viral prime-254
boost vaccination, IL-4 and IL-13 can dampen the avidity of HIV-specific CD8+ T cells 255
[24, 27]. In this study, we report that IL-4 and IL-13 can dampen CD8 expression levels 256
on anti-viral CD8+ T cells following HIV-1 recombinant pox viral prime-boost257
vaccination. Furthermore, we also report that reduced expression levels of CD8 was a 258
feature of low avidity anti-viral CD8+ T cells that developed in various pox-viral prime-259
boost vaccination settings.260
261
Our data suggested that IL-4 and IL-13 selectively regulated the expression levels of 262
CD8, but not other T cell avidity markers such as TCR, CD2, CD11a and lck on anti-263
viral CD8+ T cells following recombinant HIV-1 pox viral prime-boost vaccination. To264
our knowledge, this is the first report to show the involvement of IL-13 in regulating 265
CD8 expression levels on anti-viral CD8+ T cells. Previously, Xiao et al [34] have 266
shown that CD8 densities are down-regulated on anti-viral CD8+ T cells following 267
cognate antigen encounter during pox virus infections. In Wijesundara et al [26], we 268
have shown that naïve CD8+ T cells in the absence of IL-4 and IL-13 signalling (i.e. in269
IL-4 -/-, IL-13 -/- and STAT6 -/- mice) express lower levels of IL-4 receptor D making 270
them less responsive to these cytokines during T cell priming. Therefore, we propose 271
that IL-4/IL-13 signalling through activation of STAT6 promotes greater down-272
regulation of CD8 densities on naïve CD8+ T cells following cognate antigen encounter 273
during pox virus infection and vaccination. In agreement with this proposed mechanism, 274
previous reports showing that IL-4 exposure during naïve T cell priming can down-275
regulate CD8 expression levels to reduce the anti-viral capacity of effector CD8+ T cells  276
[35-36]. Interestingly, type I interferons (IFN-I) have also been shown to reduce CD8 277
expression levels and avidity of anti-viral CD8+ T cells [34]. Therefore, it would be of 278
interest to also investigate whether IFN-I cooperate synergistically with IL-4 and/or IL-279
13 in down-regulating CD8 expression levels on anti-viral CD8+ T cells following pox280
virus infection or vaccination. 281
282
Belyakov et al [37-38] have shown that mucosal vaccination strategies are efficient in 283
inducing high avidity anti-viral CD8+ T cells particularly at tissues closer to the sites of 284
immunization. Our initial studies have shown that mucosal i.n./i.m. HIV-1 recombinant 285
pox viral vaccination promotes the development of high avidity HIV-specific CD8+ T286
cells that produce low levels of IL-4 and IL-13 at both mucosal and systemic 287
compartments [25]. In the current study mucosal HIV-1 recombinant pox viral 288
vaccination strategies were found to enhance CD8 expression levels on HIV-specific 289
CD8+ T cells, which correlated with T cell avidity. Several other studies, including ours 290
have shown that mucosal vaccination strategies can induce robust CD8+ T cell 291
responses that can protect macaques against simian immunodeficiency virus challenge 292
[39-41]. Our recent work [24] and the current study collectively show that mucosal 293
vaccination strategies that temporarily inhibit IL-13 function (i.e. IL-13RD2 adjuvanted 294
vaccines) can enhance CD8 densities and avidity of HIV-specific CD8+ T cells with 295
better protective outcomes. These findings are consistent with Ahlers et al [23] study296
showing that immunization of mice with peptide vaccine constructs in conjunction with 297
granulocyte macrophage colony stimulating factor and IL-13RD2-Fc antibodies can 298
enhance the cytotoxic activity of HIV-specific CD8+ T cells and protection. Our recent 299
studies demonstrated that the excellent quality HIV-specific CD8+ T cells generated 300
following mucosal vaccination could be further improved when IL-4 and IL-13 301
functions are inhibited at the mucosae [24]. Interestingly, Isakov et al [42] have shown 302
that IL-15 plays an important role in enhancing avidity of anti-viral CD8+ T cells 303
following mucosal immunization, which is consistent with Oh et al [43] where IL-15 304
was shown to enhance CD8 densities and avidity of anti-viral CD8+ T cells. Therefore, 305
development of vaccines that prevent significant down-regulation of CD8 densities on 306
antigen-specific CD8+ T cells offer exciting prospects for developing efficacious307
vaccines against intracellular mucosal pathogens such as HIV-1.308
309
The establishment of polyfunctional anti-viral CD8+ T cells have been shown to 310
correlate with resistance to HIV-1 acquisition in elite controllers of HIV-1 infection [10, 311
18-19, 44]. Even though polyfunctionality correlates with avidity of anti-viral CD8+ T312
cells [10, 33], regulation of molecules that can affect both T cell avidity and 313
polyfunctionality is not well understood. In the current study, enhancement in CD8 314
expression levels highly correlated with enhancement in avidity and polyfunctionality 315
of HIV-specific CD8+ T cells following pox viral vaccination. Furthermore, blocking 316
CD8 availability significantly reduced the polyfunctional capacity and avidity of HIV-317
specific CD8+ T cells. Similar findings have been obtained on polyclonal influenza-318
specific CD8+ T cells following influenza virus infection of mice [33]. Thus, monitoring 319
CD8 expression levels could be used as a predictor of both avidity and polyfunctional 320
capacity of anti-viral CD8+ T cells. The caveat here is that IFN-J, TNF-D and IL-2321
production by lymphocytic choriomeningitis virus (LCMV)-specific monoclonal P14 322
transgenic CD8+ T cells can occur independently of CD8, especially during later stages 323
of LCMV infection [14, 45]. Therefore, it is likely that according to different viruses 324
and/or the infection state (i.e. acute or chronic) multiple redundant mechanisms may be 325
involved in regulating polyfunctionality of anti-viral CD8+ T cells. These mechanisms 326
may include regulation of lipid raft formation [46] and molecules such as TCR [47], IL-327
4 receptor D [26], lck [14] and IL-15 receptor D [43] on CD8+ T cells.328
329
Most vaccination strategies against HIV-1 to date have mainly focused in the induction 330
of either neutralizing antibodies or CD8+ T cell responses against HIV-1. However, the 331
induction of heterosubtypic immunity (both neutralizing antibody and CD8+ T cell 332
responses) is expected to be beneficial in generating optimal protective immunity 333
against HIV-1 [2]. We have now shown that HIV-1 recombinant pox viral vaccination334
strategies that inhibit IL-13 function can enhance the quality of anti-viral CD8+ T cell 335
immunity most likely through up-regulation of CD8 expression levels on anti-viral 336
CD8+ T cells [24]. We anticipate that such strategies could also enhance the quality of 337
antibody immunity, as enhanced IgE production has been reported to correlate with 338
enhanced pathogenesis of HIV-1 infections and cytokines such as IL-4 and IL-13 are 339
known to mediate isotype switching of antibodies to IgE [48-50].340
341
In conclusion, we have demonstrated that IL-4/IL-13 can mediate the down-regulation 342
of CD8 expression levels and dampen the avidity/polyfunctionality of anti-viral CD8+ T343
cells following vaccination. We have also shown that HIV-1 recombinant pox viral 344
mucosal vaccination strategies and recombinant pox viral vaccines that can transiently 345
inhibit IL-13 activity at the vaccination site can enhance CD8 expression levels and 346
avidity of anti-viral CD8+ T cells. We propose that in the absence of IL-4 and IL-13347
signalling, anti-viral CD8+ T cells express higher amounts of CD8 allowing these cells 348
to build high avidity interactions with cognate pMHC-I complexes presented on virus 349 
infected cells. This should facilitate high avidity CD8+ T cells to maintain more durable 350 
interactions with virus-infected cells allowing them to exert effector functions 351 
efficiently. Thus, we believe that vaccine strategies that inhibit IL-4/IL-13 activity offer 352 
great promise for future vaccines against many chronic infections including HIV-1 that 353 
require high avidity CD8+ T cells for protective immunity.  354 
355 
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Figure captions525
Fig. 1. IL-4 and IL-13 dampen CD8 densities on anti-viral CD8+ T cells following526
recombinant HIV-1 vaccination and VV-WR infection of mice. (A) Representative 527
histogram plots showing expression of the indicated T cell avidity markers on KdGag197-528
205 tetramer specific CD8+ splenocytes obtained from WT, IL-13 -/-, IL-4 -/- and STAT6 -529
/- BALB/c mice prime-boost vaccinated i.n FPV-HIV/ i.m.VV-HIV 14 days apart. (B 530
and C) MFI representing the expression of the indicated markers (B) or CD8E:CD8D531
expression ratio (C) calculated using MFI values on KdGag197-205 tetramer specific CD8+532
splenocytes from mice (n = 4) prime-boost vaccinated in (A). (D) MFI representing the 533
expression of CD8D on KdA5275-83 tetramer specific CD8+ splenocytes from mice (n = 534
6) of indicated genetic background infected i.p. for 7 days with VV-WR. Statistical 535
significance of the data from B-D is shown relative to BALB/c WT mice using one-way 536
ANOVA (Dunnett’s multiple comparison post-hoc test). (E) MFI representing CD8D537
expression on KdGag197-205 tetramer specific CD8+ splenocytes from BALB/c WT mice 538
(n = 4) prime-boost vaccinated i.n./i.n., i.n./i.m. or i.m./i.m.  14 days apart with FPV-539
HIV/VV-HIV. Statistical significance of the data was calculated using one-way 540
ANOVA (Tukey’s multiple comparison post-hoc test). (F) MFI representing CD8D541
expression on KdGag197-205 tetramer specific CD8+ splenocytes from BALB/c WT mice 542
(n = 4) prime-boost vaccinated i.n./i.m. with FPV-HIV/VV-HIV (control) or FPV-HIV-543
IL-13RD2/VV-HIV-IL-13RD2 (IL-13 inhibitor vaccine). Statistical significance of the 544
data was calculated using a student’s unpaired t-test. Data presented in this entire figure 545
is representative of at least two independent experiments and the error bars depict the 546
SEM. ns – p > 0.05; * - p < 0.05; ** - p < 0.01; *** - p < 0.001.547
548
549
Fig. 2. Enhancement of CD8 densities correlate with enhancement in cytokine 550 
polyfunctionality of HIV-specific CD8+ T cells from recombinant HIV-1 prime-boost 551 
vaccinated mice. RBC-depleted splenocytes from i.n. FPV-HIV/i.m. VV-HIV (14 days 552 
apart) prime-boost vaccinated BALB/c WT mice (n = 4) were stimulated with 0.1 Pg/ml 553 
of KdGag197-205 peptide and analysed for expression of CD8D, CD8E and IFN-J on 554 
cytokine producing CD8+ T cells. A, Representative dot plots from a peptide 555 
unstimulated or stimulated culture where IFN-J+ TNF-D- IL-2-, IFN-J+ TNF-D+ IL-2- 556 
and IFN-J+ TNF-D+ IL-2+ CD8+ T cells were gated for analysis. (B) Representative 557 
histogram plots showing the expression of CD8D, CD8E and IFN-J on different 558 
polyfunctional populations of KdGag197-205 specific CD8+ T cells. (C) MFI values 559 
representing the expression of the indicated proteins on different polyfunctional 560 
populations of KdGag197-205 specific CD8+ T cells. Each line is representative of an 561 
individual mouse from a total of four mice examined. Data presented in this figure is 562 
representative of at least two independent experiments. A paired t-test was used to 563 
determine the statistical significance of the data. ns – p > 0.05; * - p < 0.05; ** - p < 564 
0.01; *** - p < 0.001. 565 
566 
Fig. 3. CD8 is required by KdGag197-205 specific CD8+ T cells to optimally engage with 567 
KdGag197-205 tetramer. Splenocytes obtained from i.n. FPV-HIV/i.m. VV-HIV (14 days 568 
apart) prime-boost vaccinated BALB/c WT mice (n = 4) were incubated with varying 569 
concentrations of purified anti-CD8E.2 prior to staining with KdGag197-205 tetramer. 570 
Representative histogram plot (A) or mean (n = 4) percentage of maximum KdGag197-205 571 
tetramer binding (B) on KdGag197-205 tetramer specific CD8+ splenocytes is shown. The 572 
numbers in the histogram plot represents the concentration (Pg/ml) of anti-CD8E.2 used 573 
for CD8 blocking. The data is representative of three independent experiments and the 574 
error bars depict the SEM. 575 
576 
Fig. 4. IL-4 and IL-13 can regulate CD8 expression levels and modulate T cell quality 577 
of KdGag197-205 specific CD8+ T cells following recombinant HIV-1 prime-boost 578 
vaccination. WT, IL-13 -/-, IL-4 -/- and STAT6 -/- BALB/c mice (n = 5-8) were i.n. FPV-579 
HIV/i.m. VV-HIV (14 days apart) prime-boost vaccinated. Splenocytes from these mice 580 
with (1 Pg/ml anti-CD8E.2) or without (mock) CD8 blocking were stimulated using 0.1 581 
Pg/ml of KdGag197-205 peptide for ICS or stained using KdGag197-205 tetramer for 582 
tetramer dissociation. (A) Representative dot plots showing TNF-D and IL-2 production 583 
on gated IFN-J+ CD8+ splenocytes from vaccinated mice that were stimulated with 584 
KdGag197-205 peptide in the absence of CD8 blocking. (B) Number of IFN-J+ TNF-D+ 585 
IL-2+ KdGag197-205 specific CD8+ T cells that developed in vaccinated mice (n = 5). (C) 586 
The proportion of IFN-J+ CD8+ splenocytes that also produced TNF-D and IL-2 in the 587 
absence or presence of CD8 blocking of splenocytes during KdGag197-205 peptide 588 
stimulation. (D) Percentage of maximum KdGag197-205 tetramer binding of CD8+ T cells 589 
following tetramer dissociation for 60 minutes in the absence or presence of CD8 590 
blocking (n = 8). The data in this figure is representative of 2-3 independent 591 
experiments and the error bars depict the SEM. Statistical significance of the data was 592 
calculated using a one-way ANOVA relative to WT mice (Dunnett’s multiple 593 
comparison post-hoc test). ns- p > 0.05; * - p < 0.05; ** - p < 0.01. 594 
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